Baytril®   
 (enrofloxacin)  
 Antibacterial Injectable Solution 2.27%  
 For Dogs Only United States - English - NLM (National Library of Medicine)

baytril® (enrofloxacin) antibacterial injectable solution 2.27% for dogs only

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

BAYTRIL- enrofloxacin tablet, film coated United States - English - NLM (National Library of Medicine)

baytril- enrofloxacin tablet, film coated

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

BAYTRIL TASTE TABS- enrofloxacin tablet, chewable United States - English - NLM (National Library of Medicine)

baytril taste tabs- enrofloxacin tablet, chewable

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin)taste tabs® antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or gia

ENROFLOXACIN powder United States - English - NLM (National Library of Medicine)

enrofloxacin powder

yicheng chemical corp. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 1 kg in 1 kg

ENROFLOXACIN BASE powder United States - English - NLM (National Library of Medicine)

enrofloxacin base powder

darmerica - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 1 kg in 1 kg

ENROFLOXACIN powder United States - English - NLM (National Library of Medicine)

enrofloxacin powder

attix pharmaceuticals - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 5 kg in 5 kg

ENROFLOXACIN HCL powder United States - English - NLM (National Library of Medicine)

enrofloxacin hcl powder

attix pharmaceuticals - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 5 kg in 5 kg

ENROSITE FLAVORED- enrofloxacin tablet United States - English - NLM (National Library of Medicine)

enrosite flavored- enrofloxacin tablet

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

FLUROXIN FLAVORED- enrofloxacin tablet United States - English - NLM (National Library of Medicine)

fluroxin flavored- enrofloxacin tablet

aspen veterinary resources®, ltd - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

ENROFLOXACIN tablet
ENROFLOXACIN FLAVORED- enrofloxacin tablet United States - English - NLM (National Library of Medicine)

enrofloxacin tablet enrofloxacin flavored- enrofloxacin tablet

zyvet animal health inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.